CO5580782A2 - Antibioticos de glicopeptido-cefalosporina entrecruzados - Google Patents

Antibioticos de glicopeptido-cefalosporina entrecruzados

Info

Publication number
CO5580782A2
CO5580782A2 CO04032190A CO04032190A CO5580782A2 CO 5580782 A2 CO5580782 A2 CO 5580782A2 CO 04032190 A CO04032190 A CO 04032190A CO 04032190 A CO04032190 A CO 04032190A CO 5580782 A2 CO5580782 A2 CO 5580782A2
Authority
CO
Colombia
Prior art keywords
group
independently selected
alkylene
optionally substituted
hydrogen
Prior art date
Application number
CO04032190A
Other languages
English (en)
Inventor
Paul Fatheree
Martin S Linsell
Daniel D Long
Daniel Marquess
Edmund J Moran
Matthew B Nodwell
S Derek Turner
James Aggen
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of CO5580782A2 publication Critical patent/CO5580782A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/40Unsubstituted amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

1.- Un compuesto de formula I.o una sal farmacéuticamente aceptable de este, en donde X1 y X2 son independientemente seleccionados del grupo consistente de hidrógeno y cloro;R1 es -Ya -(W)n-Yb-;W es seleccionado del grupo consistente de -O-, -N(Rd)-, -S-, -S(O)-, -S(O)2, cicloalquileno C3-6, arileno C6-10 y heteroarileno C2-9; donde cada grupo arileno, cicloalquileno y heteroarileno está opcionalmente sustituido con 1 a 3 sustituyentes independientemente seleccionados de Rb;Ya y Yb son independientemente alquileno C1-5, o cuando W es cicloalquileno, arileno o heteroarileno, Ya y Yb son independientemente seleccionados de un grupo consistente de un enlace covalente y alquileno C1-5; en donde cada grupo alquileno está opcionalmente sustituido con 1 a 3 sustituyentes independientemente seleccionados de -ORd-, -NRdRe, -CO2Rd, -C(O)NRdRe, y S(O)2NRdRe.R2 es hidrógeno o alquilo C1-6;Cada R3 es independientemente seleccionado del grupo consistente de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, arilo C6-10, heteroarilo C2-9, heterocíclico C3-6 y Ra; o dos grupos adyacentes R3 están unidos para formar alquileno C3-6 o -O-(alquileno C1-6)-O-; en donde cada grupo alquilo, alquileno, alquenilo y alquinilo está opcionalmente sustituido con 1 a 3 sustituyentes independientemente seleccionados del grupo consistente de Ra y Rc; y cada grupo arilo, cicloarilo, heteroarilo y heterocíclico está opcionalmente sustituido con 1 a 3 sustituyentes independientemente seleccionados del grupo consistente de Rb;Uno entre R4 y R5 es hidroxi y el otro es hidrógeno;R6 y R7 son independientemente hidrógeno o metilo; ...
CO04032190A 2001-10-12 2004-04-05 Antibioticos de glicopeptido-cefalosporina entrecruzados CO5580782A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32888901P 2001-10-12 2001-10-12

Publications (1)

Publication Number Publication Date
CO5580782A2 true CO5580782A2 (es) 2005-11-30

Family

ID=23282891

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04032190A CO5580782A2 (es) 2001-10-12 2004-04-05 Antibioticos de glicopeptido-cefalosporina entrecruzados

Country Status (30)

Country Link
US (11) US6974797B2 (es)
EP (1) EP1434779B1 (es)
JP (3) JP4249023B2 (es)
KR (1) KR100888660B1 (es)
CN (2) CN100358901C (es)
AT (1) ATE314376T1 (es)
AU (1) AU2002332111B2 (es)
BR (2) BRPI0213154B1 (es)
CA (1) CA2463544C (es)
CO (1) CO5580782A2 (es)
DE (1) DE60208404T2 (es)
DK (1) DK1434779T3 (es)
EA (1) EA007001B1 (es)
ES (1) ES2254738T3 (es)
HK (1) HK1066007A1 (es)
HR (1) HRP20040243B1 (es)
HU (1) HU230158B1 (es)
IL (2) IL160846A0 (es)
IS (1) IS2422B (es)
MX (1) MXPA04003273A (es)
NO (1) NO334092B1 (es)
NZ (1) NZ531576A (es)
PL (1) PL209757B1 (es)
RS (1) RS50888B (es)
SI (1) SI1434779T1 (es)
SK (1) SK2052004A3 (es)
TW (1) TWI335332B (es)
UA (1) UA80098C2 (es)
WO (1) WO2003031449A2 (es)
ZA (1) ZA200402732B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
ES2384707T3 (es) 2002-05-24 2012-07-11 Theravance, Inc. Antibióticos entrecruzados de glucopéptidos y cefalosporinas
WO2004113350A1 (en) * 2003-05-23 2004-12-29 Theravance, Inc. Cross-linked glycopeptide - cephalosporin antibiotics
JP4555823B2 (ja) * 2003-07-11 2010-10-06 セラヴァンス, インコーポレーテッド 架橋されたグリコペプチド−セファロスポリン抗生物質
KR100808414B1 (ko) * 2004-06-08 2008-02-29 엘지전자 주식회사 이동단말의 클라이언트 세션 복구방법
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
EA028342B1 (ru) 2011-09-09 2017-11-30 Мерк Шарп И Доум Корп. Способы лечения пневмонии
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
TWI608845B (zh) * 2013-03-13 2017-12-21 施萬生物製藥抗生素Ip有限責任公司 抗生素化合物之鹽酸鹽
GEP201706779B (en) * 2013-03-13 2017-11-27 Theravance Biopharma Antibiotics Ip Llc Crystalline form of a substituted thiazolylacetic acid triethylamine salt
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
AU2014227660B2 (en) 2013-03-15 2014-11-06 Merck Sharp & Dohme Llc Ceftolozane antibiotic compositions
US20140274991A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US10943049B2 (en) * 2018-09-28 2021-03-09 Taiwan Semiconductor Manufacturing Co., Ltd. Rule check violation prediction systems and methods
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US457926A (en) * 1891-08-18 Steam-engine
US4668783A (en) * 1974-12-19 1987-05-26 Takeda Chemical Industries, Ltd. Thiazolylacetamido cephalosporin compounds
FR2347706A1 (fr) * 1976-04-08 1977-11-04 Issec Labo Physicochimie Appli Nouveau procede photographique d'impression en couleurs sur divers substrats
JPS5994B2 (ja) * 1976-09-14 1984-01-05 富士写真フイルム株式会社 感光性組成物
US4155909A (en) * 1977-06-13 1979-05-22 Philip Morris Incorporated 2-Alkyl nicotinoids and processes for their production
DE2758001A1 (de) * 1977-12-24 1979-07-12 Hoechst Ag Cephalosporinderivate und verfahren zu ihrer herstellung
US4284631A (en) * 1978-07-31 1981-08-18 Fujisawa Pharmaceutical Co., Ltd. 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them
GB2033377B (en) 1978-09-11 1983-05-05 Fujisawa Pharmaceuticalco Ltd Cephem compounds and processes for preparation thereof
US4341775A (en) 1978-09-11 1982-07-27 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4220761A (en) 1978-09-12 1980-09-02 Fujisawa Pharmaceutical Co., Ltd. 7-[Substituted oximinoacetamido]-3-[hydroxy alkyltetrazolo]cephalosporin derivatives
DE3006888A1 (de) * 1980-02-23 1981-09-10 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
US4427677A (en) * 1980-12-31 1984-01-24 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DE3118732A1 (de) * 1981-05-12 1982-12-02 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
JPS5859991A (ja) * 1981-09-14 1983-04-09 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
US4427877A (en) * 1981-09-28 1984-01-24 Raychem Corporation Printing on low surface energy polymers
DE3207840A1 (de) * 1982-03-04 1983-09-15 Hoechst Ag, 6230 Frankfurt "cephalosporinderivate und verfahren zu ihrer herstellung"
DE3316798A1 (de) * 1983-05-07 1984-11-08 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von cephemverbindungen
JPS6041682A (ja) 1983-08-16 1985-03-05 Meiji Seika Kaisha Ltd 新規セフアロスポリン化合物及びその製造法
DE3418482A1 (de) * 1984-05-18 1985-11-21 Basf Ag, 6700 Ludwigshafen Magnetische aufzeichnungstraeger
US4840945A (en) * 1985-04-01 1989-06-20 Mochida Pharmaceutical Co., Ltd. Cephalosporin derivatives
US4921851A (en) 1986-06-09 1990-05-01 Takeda Chemical Industries, Ltd. Cephem compounds, their production and use
AU1630988A (en) 1987-05-30 1988-12-01 Kyoto Pharmaceutical Industries, Ltd. Cephalosporin compound and pharmaceutical composition thereof
US4974797A (en) * 1988-03-17 1990-12-04 Consolidated Rail Corporation Hot bearing simulator
US4943587A (en) * 1988-05-19 1990-07-24 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
US5693791A (en) * 1995-04-11 1997-12-02 Truett; William L. Antibiotics and process for preparation
AUPN955596A0 (en) * 1996-04-30 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New compound
JP3906938B2 (ja) * 1997-02-18 2007-04-18 富士フイルム株式会社 画像再生方法及び画像データ管理方法
EP1060189A1 (en) * 1998-02-20 2000-12-20 Advanced Medicine, Inc. Derivatives of glycopeptide antibacterial agents
US6437119B1 (en) * 1998-05-07 2002-08-20 William Lawrence Truett Compounds formed from two or three antibiotics and their processes of preparation
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
HU230190B1 (hu) * 1998-12-23 2015-09-28 Theravance, Inc Glikopeptidszármazékok és ezeket tartalmazó gyógyászati kompozíciók
AU4308000A (en) 1999-04-19 2000-11-02 Attila Lenkehegyi Dually adjustable electromechanical means for handling and system of these, and dually adjustable digital potentiometer
US20070154948A1 (en) 1999-05-24 2007-07-05 Christensen Burton G Novel antibacterial agents
DE60103991T2 (de) 2000-04-06 2005-08-25 Unomedical A/S Verbindungsvorrichtung
JP4107792B2 (ja) * 2000-08-28 2008-06-25 独立行政法人科学技術振興機構 可視光応答性を有する金属オキシナイトライドからなる光触媒
US6885138B1 (en) * 2000-09-20 2005-04-26 Samsung Electronics Co., Ltd. Ferroelectric emitter
US7087482B2 (en) * 2001-01-19 2006-08-08 Samsung Electronics Co., Ltd. Method of forming material using atomic layer deposition and method of forming capacitor of semiconductor device using the same
US20030009681A1 (en) * 2001-07-09 2003-01-09 Shunji Harada Digital work protection system, recording medium apparatus, transmission apparatus, and playback apparatus
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
ES2384707T3 (es) 2002-05-24 2012-07-11 Theravance, Inc. Antibióticos entrecruzados de glucopéptidos y cefalosporinas
WO2004113350A1 (en) 2003-05-23 2004-12-29 Theravance, Inc. Cross-linked glycopeptide - cephalosporin antibiotics
JP4555823B2 (ja) * 2003-07-11 2010-10-06 セラヴァンス, インコーポレーテッド 架橋されたグリコペプチド−セファロスポリン抗生物質
CN100352223C (zh) * 2004-12-31 2007-11-28 华为技术有限公司 一种在城域传输网络中保护数据业务的方法
EP2231589B1 (en) 2007-12-11 2013-02-13 Theravance, Inc. Aminotetralin compounds as mu opioid receptor antagonists

Also Published As

Publication number Publication date
US20100197569A1 (en) 2010-08-05
US7341993B2 (en) 2008-03-11
JP2009040795A (ja) 2009-02-26
IS2422B (is) 2008-10-15
US20030130173A1 (en) 2003-07-10
CA2463544A1 (en) 2003-04-17
HK1066007A1 (en) 2005-03-11
US20080194464A1 (en) 2008-08-14
US20080039374A1 (en) 2008-02-14
BRPI0213154B1 (pt) 2018-01-16
PL209757B1 (pl) 2011-10-31
US7655621B2 (en) 2010-02-02
HU230158B1 (hu) 2015-09-28
PL368451A1 (en) 2005-03-21
US20080039611A1 (en) 2008-02-14
JP2009143962A (ja) 2009-07-02
EA200400530A1 (ru) 2004-08-26
WO2003031449A2 (en) 2003-04-17
CA2463544C (en) 2011-03-29
IS7172A (is) 2004-03-04
EA007001B1 (ru) 2006-06-30
WO2003031449A3 (en) 2003-08-28
US7612037B2 (en) 2009-11-03
CN1329397C (zh) 2007-08-01
DK1434779T3 (da) 2006-01-30
US7728127B2 (en) 2010-06-01
ATE314376T1 (de) 2006-01-15
DE60208404D1 (de) 2006-02-02
CN1781916A (zh) 2006-06-07
BR0213154A (pt) 2004-08-10
YU29504A (sh) 2006-08-17
DE60208404T2 (de) 2006-07-27
SK2052004A3 (en) 2004-10-05
US6974797B2 (en) 2005-12-13
US20050239691A1 (en) 2005-10-27
NZ531576A (en) 2006-10-27
US20080194465A1 (en) 2008-08-14
NO20041912L (no) 2004-05-10
US20080045721A1 (en) 2008-02-21
AU2002332111B2 (en) 2008-04-17
EP1434779B1 (en) 2005-12-28
UA80098C2 (en) 2007-08-27
US8044195B2 (en) 2011-10-25
US20120214967A1 (en) 2012-08-23
SI1434779T1 (sl) 2006-06-30
EP1434779A2 (en) 2004-07-07
TWI335332B (en) 2011-01-01
ZA200402732B (en) 2005-05-25
US20080051577A1 (en) 2008-02-28
CN100358901C (zh) 2008-01-02
HUP0401596A2 (hu) 2004-12-28
HUP0401596A3 (en) 2013-06-28
HRP20040243B1 (en) 2008-07-31
US7649080B2 (en) 2010-01-19
US7553962B2 (en) 2009-06-30
JP4249023B2 (ja) 2009-04-02
IL160846A0 (en) 2004-08-31
MXPA04003273A (es) 2004-07-08
US8557978B2 (en) 2013-10-15
JP4445028B2 (ja) 2010-04-07
US7601690B2 (en) 2009-10-13
NO334092B1 (no) 2013-12-09
RS50888B (sr) 2010-08-31
HRP20040243A2 (en) 2004-08-31
KR20050035122A (ko) 2005-04-15
US7713931B2 (en) 2010-05-11
KR100888660B1 (ko) 2009-03-13
ES2254738T3 (es) 2006-06-16
JP2005507907A (ja) 2005-03-24
IL160846A (en) 2010-05-17
US20080108558A1 (en) 2008-05-08
CN1568325A (zh) 2005-01-19

Similar Documents

Publication Publication Date Title
CO5580782A2 (es) Antibioticos de glicopeptido-cefalosporina entrecruzados
AR120080A1 (es) Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
AR121044A1 (es) Inhibidores de egfr
AR115885A1 (es) Compuestos derivados de 1h-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y su uso en combinación con un agente de inmunoterapia anticancerígeno
AR112687A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción tricíclica, conjugados de estos y métodos y usos de estos
AR048607A1 (es) Derivados (poli)aminoalquilaminoacetamida de la epipodofilotoxina, proceso de preparacion de los mismos y sus aplicaciones terapeuticas como agentes anticancerosos
AR114793A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR112338A2 (es) Arilciclohexiléteres de dihidro-tetraazabenzoazuleno
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR056327A1 (es) Compuestos de nucleosidos para el tratamiento de infecciones virales
AR042583A1 (es) Macrolidos
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR040047A1 (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR116315A1 (es) Compuestos de triazolo-pirimidina y usos de los mismos
AR048376A1 (es) C- glicosidos heterociclos fusionados sustituidos
CO5580788A2 (es) Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas
AR047817A1 (es) Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica
AR112392A1 (es) Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende

Legal Events

Date Code Title Description
FG Application granted